The clinical proton therapy education program was developed based on the experience of Washington University in delivery of best-in-class clinical training. The first Washington University proton therapy course was delivered last year and brought together more than 30 international attendees.

The MEVION S250 at Siteman Cancer Center has been operational since December 2013. In that time, the technology has treated nearly 250 cancer patients (75 percent adults and 25 percent pediatric patients) with a wide variety of complex tumors, including 44 percent in the intracranial region, 24 percent in the lungs, 10 percent in the craniospinal region, 7 percent in the prostate and 5 percent in the head and neck.


Nine Mevion proton therapy systems are currently operational or under installation at leading cancer centers in the United States and in Europe. To learn more about Mevion during ASTRO, please visit booth 650 in the exhibit hall.

About Mevion Medical Systems

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers.

Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com.

HYPERSCAN has not been cleared by the USFDA for clinical use.

Back to HCB News

More HCB News